Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Ose Pharma International S.A. buy melinda

Ose Pharma International S.A.
Start price
€3.82
27.02.18 / 50%
Target price
€9.00
20.04.18
Performance (%)
13.35%
End price
€4.33
20.04.18
Summary
This prediction ended on 20.04.18 with a price of €4.33. The BUY prediction by melinda finished with a performance of 13.35%. melinda has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Ose Pharma International S.A. 10.498% 10.498% 67.838% -
iShares Core DAX® -0.922% -1.078% 12.165% 16.796%
iShares Nasdaq 100 0.371% -0.556% 38.622% 49.370%
iShares Nikkei 225® 2.224% -2.825% 19.015% 4.643%
iShares S&P 500 -0.026% -0.788% 28.485% 42.479%

According to melinda what are the pros and cons of Ose Pharma International S.A. for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Cons

Comments by melinda for this prediction

In the thread Ose Pharma International S.A. diskutieren
Prediction Buy
Perf. (%) 13.35%
Target price 9.000
Change
Ends at 20.04.18

SektorBiotechnologische und medizinische Forschung



Beruf
Logo OSE Immunotherapeutics
Nach der Fusion mit Effimune nahm OSE Pharma den Namen OSE Immunotherapeutics an. Die neue Gruppe ist auf die Entwicklung innovativer Therapien zur Aktivierung oder Regulierung des Immunsystems zur Wiederherstellung von Systemstörungen in den Bereichen Immunonkologie, Autoimmunkrankheiten und Transplantationen spezialisiert.
Das Unternehmen verfügt über ein ausgewogenes Produktportfolio und ein diversifiziertes Risikoprofil:
- Flaggschiffprodukt in der Immunonkologie Tedopi® in der Phase-3-Aufzeichnung (in Kombination mit einem inhibitorischen Kontrollpunkt, Tedopi®-Phase 2, die 2017 geplant ist);
- Hauptkandidat in der Immunregulation: FR104 entwickelt in Zusammenarbeit mit J & J in Phase 2 und Effi-7 in der präklinischen Phase / Autoimmunkrankheiten und Transplantationen;
- neue Generation von Inhibitor Checkpoints für MDSC / TAM: Effi-DEM in der präklinischen Entwicklung.

Anzahl der Angestellten : 22 Personen.



melinda 
0
Report Share
27.02.18
Prediction Buy
Perf. (%) 13.35%
Target price 9.000
Change
Ends at 20.04.18

(Vom Mitglied beendet)

melinda 
0
Report Share
20.04.18

Stopped prediction by melinda for Ose Pharma International S.A.

buy
Ose Pharma International S.A.

Start price
Target price
Perf. (%)
€7.32
04.05.22
€9.00
04.05.23
-49.42%
05.05.23

Could be worthwhile Investment >10% per year
melinda 
04.05.22 50%
buy
Ose Pharma International S.A.

Start price
Target price
Perf. (%)
€9.99
16.10.21
-
16.10.22
-26.78%
04.05.22

Could be worthwhile Investment >10% per year
melinda 
16.10.21 0%
sell
Ose Pharma International S.A.

Start price
Target price
Perf. (%)
€11.56
21.09.21
€9.00
21.09.22
-13.58%
16.10.21

Could be worthwhile Investment >10% per year
melinda 
21.09.21 50%
buy
Ose Pharma International S.A.

Start price
Target price
Perf. (%)
€9.36
06.11.20
€14.00
06.11.21
23.50%
21.09.21

Could be worthwhile Investment >10% per year
melinda 
06.11.20 50%
buy
Ose Pharma International S.A.

Start price
Target price
Perf. (%)
€4.52
24.06.17
€6.80
19.12.17
-19.47%
19.12.17

Could be worthwhile Investment >10% per year
melinda 
14.08.19 50%
buy
Ose Pharma International S.A.

Start price
Target price
Perf. (%)
€4.52
24.06.17
€6.80
19.12.17
-19.47%
19.12.17

Could be worthwhile Investment >10% per year
melinda 
14.08.19 50%
buy
Ose Pharma International S.A.

Start price
Target price
Perf. (%)
€7.35
08.06.16
€10.00
08.12.16
-11.84%
08.12.16

Could be worthwhile Investment >10% per year
melinda 
14.08.19 50%